Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient

Proprietary Educational Format:

Activity Overview

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

0.25 CE Credit(s)
Expires: October 10, 2022

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Faculty

Ison 300x400

Michael G. Ison, MD, MS

Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Zimmerman 300x400

Richard K. Zimmerman, MD, MPH, MS

Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA